REASSURE: The Effect of Rimonabant on HbA1c in Overweight or Obese Patients With Type 2 Diabetes Not Adequately Controlled on 2 Oral Antidiabetic Agents

List of Inclusion and Exclusion criteria: Inclusion Criteria: * History of Type 2 diabetes * HbA1c between 7% to 9% (inclusive) * BMI ≥ 27kg/m² and BMI ≤ 40kg/m² * Currently taking Metformin and Sulfonylurea. Exclusion Criteria: * Uncontrolled serious psychiatric illness such as major depression * Current use of antidepressants * Severe renal impairment (creatinine clearance less than 30ml/min) * Severe hepatic impairment known by investigator or Aspartate Aminotransferase and/or Alanine Aminotransferase \> 3 times Upper Limit Normal * Patient treated for epilepsy * Pregnant or breast-feeding women * Women of childbearing potential not protected by effective contraception * Hypersentivity/intolerance to rimonabant or any of the excipents * Presence of any condition, current or anticipated that in the investigator's opinion would compromise the patient's safety * Use of insulin for longer than 1 week within 4 weeks prior to screening * Chronic use of systemic corticosteriods * Use of glitazone therapy, glucagon-like peptide or dipeptidyl peptidase IV * History of drug or alcohol abuse wihtin the last three years * Heart failure class III-IV (New York Heart Association classification) * Severe hypertension * Adminstration of the following medications: phentermine, amphetamines, orlistat, sibutramine, herbal remedies * Use of non-lipid agents known to affect lipid metabolism: retinoids, antiretrovirals, hormone replacement therapy containing estrogens, cyclosporin, thiazolidinediones (glitazones), fish oils, plant sterols * Use of ketoconazole, itraconazole, ritonavir, clarithromycin, rifampicin, phenytoin, phenobarbitone, carbamazepine or St John's Wort * Participation in a clinical study within the 4 weeks prior to randomisation * Patients involved in an existing weight loss program * Presence of chronic hepatitis * Use, or misuse, of substances of abuse * Marijuana or hashish users * History of gastrointestinal surgery for weight loss purposes or who are scheduled for such surgery within the duration of their expected participation in this study * History or presence of bulimia or laxative abuse * Non-English speaking The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.